Biopharmaceutical firm Parvus Therapeutics has signed a worldwide collaboration and licence agreement with Genentech to develop, manufacture and commercialise therapeutics?for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD) and?coeliac d